Stockscreener 앱 받기
2.03
1.00%
0.02
시간 외 거래:
2.10
0.07
+3.45%
전일 마감가:
$2.01
열려 있는:
$2.06
하루 거래량:
3.98M
Relative Volume:
0.96
시가총액:
$719.20M
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-3.9038
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
-15.77%
1개월 성능:
-6.45%
6개월 성능:
-24.81%
1년 성능:
-48.61%
1일 변동 폭
$1.99
$2.18
1주일 범위
$1.98
$2.40
52주 변동 폭
$1.8906
$4.3398
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.03 | 719.20M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus
Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus
AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Investments - GuruFocus
AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Biologics Reports Q1 2025 Financial Results - TipRanks
AbCellera (ABCL) Advances Clinical Programs with Strong Financial Position - GuruFocus
Abcellera Biologics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
AbCellera Reports Q1 2025 Business Results - BioSpace
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
AbCellera (ABCL) Misses Revenue Projections, Advances New Antibody Treatment | ABCL Stock News - GuruFocus
AbCellera Biologics Inc Reports Q1 2025 Earnings: EPS of $(0.15) Misses Estimate, Revenue Falls Short at $4.2 Million - GuruFocus
AbCellera Biologics (ABCL) Q1 Earnings Preview: Analysts Expect Lower Revenue - GuruFocus
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Abcellera at Bloom Burton: Strategic Shift in Biotech Development By Investing.com - Investing.com UK
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - BioSpace
AbCellera (ABCL) Unveils Promising Preclinical Results for T-Cel - GuruFocus
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x C - GuruFocus
AbCellera reports promising preclinical TCE cancer therapy data - Investing.com
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 | ABCL Stock News - GuruFocus
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
KeyBanc Increases Price Target for AbCellera (ABCL) Amidst Economic Concerns | ABCL Stock News - GuruFocus
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
What to Expect in the Week Ahead: Inflation Data, Bank Earnings, and More Tariff Concerns - The Globe and Mail
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):